Updated on 2025/02/27

写真a

 
MATSUNAGA Shinji
 
Organization
Graduate School of Medicine Department of Basic Medical Science Lecturer
School of Medicine Department of Medical Science
Title
Lecturer
Affiliation
Institute of Medcine

Position

  • Graduate School of Medicine Department of Basic Medical Science 

    Lecturer  2022.04 - Now

  • School of Medicine Department of Medical Science 

    Lecturer  2022.04 - Now

Degree

  • 博士（医学） （ Tottori University ）

  • 修士（薬学） （ Gifu Pharmaceutical University ）

Research Areas

  • Life Science / Pharmacology

Research Interests

  • 腫瘍血管

  • 抗癌剤

  • 腫瘍

Research subject summary

  • 腫瘍血管と腫瘍組織環境

Research Career

  • 腫瘍組織環境と血管正常化

    2013.05 - Now 

  • DNA損傷修復におけるDNA二重鎖切断修復遺伝子変異の影響

    2011.07 - 2014.03 

  • 癌患者における細菌感染と腫瘍免疫

    2007.04 - 2011.07 

Professional Memberships

  • 日本薬理学会

      Domestic

  • 日本臨床薬理学会

      Domestic

  • 日本癌学会

      Domestic

  • 日本薬学会

      Domestic

Job Career (off-campus)

  • 鳥取大学医学部病態解析医学講座   分子薬理学分野   助教

    2013.05 - 2016.06

  • University of Texas Southwestern Medical Center   Department of Radiation Oncology   Post Doctoral Fellow

    2011.07 - 2013.04

  • 鳥取大学医学部附属病院　   薬剤部   薬剤師

    2010.07 - 2011.07

  • 独立行政法人国立病院機構　米子医療センター   薬剤科   薬剤師

    2006.04 - 2010.06

Education

  • Tottori University   Doctor's Course   Graduated/Completed

    2007.04 - 2011.03

  • Gifu Pharmaceutical University   The first semester of doctoral program   Graduated/Completed

    2004.04 - 2006.03

  • Gifu Pharmaceutical University     Graduated/Completed

    2000.04 - 2004.03

Papers

  • 特集 腎性貧血:HIF-PH阻害薬への期待と課題 【各論】 HIF-PH阻害薬使用時の注意点　悪性腫瘍 Reviewed

    松永 慎司, 冨田 修平

    腎と透析   93 ( 2 )   236 - 239   2022.08（ ISSN:03852156 ）

    　More details

  • An efficient CRISPR interference-based prediction method for synergistic/additive effects of novel combinations of antituberculosis drugs Reviewed

    Samukawa N.

    Microbiology (United Kingdom)   168 ( 12 )   2022（ ISSN:13500872 ）

    　More details

  • Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice(和訳中) Reviewed

    Nishide Shunji, Uchida Junji, Matsunaga Shinji, Tokudome Kentaro, Yamaguchi Takehiro, Kabei Kazuya, Moriya Taiki, Miura Katsuyuki, Nakatani Tatsuya, Tomita Shuhei

    (公社)日本薬理学会　Journal of Pharmacological Sciences   143 ( 2 )   122 - 126   2020.06（ ISSN:1347-8613 ）

  • Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model. Reviewed

    Kabei K, Tateishi Y, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Matsunaga S, Yamaguchi T, Tomita S, Miura K

    Journal of pharmacological sciences   142 ( 3 )   93 - 100   2020.03（ ISSN:1347-8613 ）

    　More details

  • Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model. Reviewed

    Nishide S, Matsunaga S, Shiota M, Yamaguchi T, Kitajima S, Maekawa Y, Takeda N, Tomura M, Uchida J, Miura K, Nakatani T, Tomita S

    iScience   19   940 - 954   2019.09

    　More details

  • A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4. Reviewed

    Yamaguchi T, Watanabe A, Tanaka M, Shiota M, Osada-Oka M, Sano S, Yoshiyama M, Miura K, Kitajima S, Matsunaga S, Tomita S, Iwao H, Izumi Y

    Journal of pharmacological sciences   139 ( 2 )   112 - 119   2019.02（ ISSN:1347-8613 ）

    　More details

  • Hypoxia-inducible factor-1α regulates energy fuel metabolism and mediates metabolic plasticity during ammonia stress response in ovarian cancer stem-like cells

    Kitajima Shojiro, Lee Kian Leong, Hikasa Hiroki, Matsunaga Shinji, Yamaguchi Takehiro, Tomita Shuhei, Araki Marito, Kato Hiroyuki, Poellinger Lorenz

    Proceedings for Annual Meeting of The Japanese Pharmacological Society   WCP2018 ( 0 )   PO4-6-39   2018（ eISSN:24354953 ）

    　More details

    <p>Ammonia is produced by cancer cells as a by-product of glutamine metabolism during rapid cell growth. Although the toxicity of ammonia has been well known, specific factors that deal with ammonia-induced cellular stress and regulate cell metabolism to survive have yet to be identified. We demonstrated that the hypoxia-inducible factor-1α (HIF-1α) is stabilised and activated during ammonia stress response. The ablation of HIF-1α promoted apoptosis caused by high levels of ammonia. Moreover, we identified glutamine synthetase (GS) as a key driver of cancer cell proliferation under ammonia stress and glutamine-dependent metabolism in ovarian cancer stem-like cells marked by the expression of CD90. Interestingly, activated HIF-1α counteracts GS function in glutamine metabolism by facilitating glycolysis leading to elevated glucose dependency. Our studies reveal the hitherto unknown functions of HIF-1α that promote metabolic plasticity during ammonia stress response in the cancer stem-like cells where GS facilitates cell proliferation and HIF-1α contributes to remodeling in energy fuel usage resulting in attenuated proliferation but conversely promoting cell survival.</p>

    DOI： 10.1254/jpssuppl.wcp2018.0_po4-6-39

    CiNii Article

  • Tumour blood vessel normalisation by prolyl hydroxylase inhibitor repaired sensitivity to chemotherapy in a tumour mouse model Reviewed

    Koyama Satoshi, Matsunaga Shinji, Imanishi Masaki, Maekawa Yoichi, Kitano Hiroya, Takeuchi Hiromi, Tomita Shuhei

    SCIENTIFIC REPORTS   7   45621   2017.03（ ISSN:2045-2322 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/srep45621

    PubMed

  • Hypoxia-Inducible Factor-1 alpha in Smooth Muscle Cells Protects Against Aortic Aneurysms-Brief Report Reviewed

    Imanishi Masaki, Chiba Yoichi, Tomita Noriko, Matsunaga Shinji, Nakagawa Toshitaka, Ueno Masaki, Yamamoto Kazuhiro, Tamaki Toshiaki, Tomita Shuhei

    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY   36 ( 11 )   2158 - +   2016.11（ ISSN:1079-5642 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1161/ATVBAHA.116.307784

    PubMed

  • Spontaneous tumor development in bone marrow-rescued DNA-PKcs(3A/3A) mice due to dysfunction of telomere leading strand deprotection Reviewed

    Zhang S., Matsunaga S., Lin Y-F, Sishc B., Shang Z., Sui J., Shih H-Y, Zhao Y., Foreman O., Story M. D., Chen D. J., Chen B. P. C.

    ONCOGENE   35 ( 30 )   3909 - 3918   2016.07（ ISSN:0950-9232 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/onc.2015.459

  • The catalytic subunit of DNA-dependent protein kinase is required for cellular resistance to oxidative stress independent of DNA double-strand break repair. Reviewed

    Li M, Lin YF, Palchik GA, Matsunaga S, Wang D, Chen BP

    Free radical biology & medicine   76   278 - 85   2014.11（ ISSN:0891-5849 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.freeradbiomed.2014.08.019

    PubMed

  • DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response. Reviewed

    Lin YF, Shih HY, Shang Z, Matsunaga S, Chen BP

    Nucleic acids research   42 ( 7 )   4463 - 73   2014.04（ ISSN:0305-1048 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/nar/gku116

    PubMed

  • DNA-PKcs activates the Chk2-Brca1 pathway during mitosis to ensure chromosomal stability. Reviewed

    Shang Z, Yu L, Lin YF, Matsunaga S, Shen CY, Chen BP

    Oncogenesis   3 ( 2 )   e85   2014.02（ ISSN:2157-9024 ）

    　More details

  • DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability. Reviewed

    3 ( 2 )   e85   2014

    　More details

    Publishing type：Research paper (scientific journal)  

  • Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Reviewed

    Yamaguchi K, Chikumi H, Shimizu A, Takata M, Kinoshita N, Hashimoto K, Nakamoto M, Matsunaga S, Kurai J, Miyake N, Matsumoto S, Watanabe M, Yamasaki A, Igishi T, Burioka N, Shimizu E

    Cancer science   103 ( 8 )   1405 - 13   2012.08（ ISSN:1347-9032 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1349-7006.2012.02330.x

    PubMed

  • Pseudomonas aeruginosa quorum-sensing molecule N-3-oxo-dodecanoyl homoserine lactone down-regulate cell surface ULBP2 on lung cancer cell lines Reviewed

    62 ( 2 )   77 - 90   2011.03（ ISSN:00440558 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    CiNii Article

  • Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. Reviewed

    Matsunaga S, Iguchi K, Usui S, Hirano K

    Anticancer research   27 ( 2 )   927 - 32   2007.03（ ISSN:0250-7005 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    PubMed

  • Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Reviewed

    Iguchi K, Matsunaga S, Nakano T, Usui S, Hirano K

    Anticancer research   26 ( 4B )   2977 - 81   2006.07（ ISSN:0250-7005 ）

    　More details

    Publishing type：Research paper (scientific journal)  

    PubMed

  • Survey of the Use of Supplements by Persons Visiting Gifu Pharmaceutical University Pharmacy Reviewed

    ADACHI Tetsuo, MATSUNAGA Shinji, KUBOTA Masafumi, TAKASHIMA Eiji, TSUCHIYA Teruo, HIRANO Kazuyuki

    Japanese Society of Pharmaceutical Health Care and Sciences, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)   31 ( 10 )   845 - 850   2005.10（ ISSN:1346342X ）

    　More details

    Publishing type：Research paper (scientific journal)  

    Amid the increasing use of supplements due to people's growing interest in their health and deregulation, there have been cases of supplements adversely affecting people's health and interacting with drugs. For this reason, pharmacists are often required to give guidance on the use of supplements.<BR>We conducted a questionnaire survey concerning the use of supplements by persons visiting the Gifu Pharmaceutical University Pharmacy, which had the following findings. Of those surveyed, 41.8% had used supplements. A large number of younger people used vitamin and mineral preparations for health maintenance and dieting purposes, and many older people used various supplements for health maintenance and as an additional treatment for diseases. Eighty-five percent of those surveyed said that they read the precautions for use, but only 55% checked warnings and adverse effects and just 59% said they were aware of interactions with drugs, indicating a lack of awareness of the risks of supplements. When pharmacists are consulted concerning the use of supplements, they should base their advice on knowledge of the patient's use of drugs and emphasize the need to improve their lifestyle so that they do not have to depend on supplements.

    DOI： 10.5649/jjphcs.31.845

    CiNii Article

▼display all

Presentations

  • 【低酸素応答を標的とした治療薬・創薬の最前線】HIF-PH阻害薬によるがん微小環境と腫瘍免疫への影響 Domestic conference

    松永 慎司, 冨田 修平

    日本薬理学雑誌  2024.05  (公社)日本薬理学会

    　More details

    HIF-PH阻害薬が本邦で承認され保険適応され,臨床で複数の薬剤が使用されており,本邦でも多くの臨床研究や症例報告がなされてきている.臨床使用に関する多くの情報が蓄積されている.しかしながら,HIF-PH阻害薬は低酸素誘導因子(HIF)のレベルを亢進させる作用機序のため,がん患者への投与には注意が必要な状況である.がん細胞において,HIFは腫瘍増殖に影響を与え,化学療法および放射線抵抗性に関与している.一方,免疫細胞においてHIFの亢進は炎症と関連しており,腫瘍進展の抑制に関与しているとされる.これら組織への影響として相反する作用は,生体モデルにおいては明らかとなっていない.そのため,生体腫瘍においてHIFの亢進が,がん治療において有益であるかどうかを明らかにすることが課題である.我々はこれまでに,担がんマウスモデルにおいてHIF-PH阻害薬の投与が腫瘍血管の正常様化を促進し,腫瘍増殖の抑制につながることを報告した.さらに,これらの現象は腫瘍浸潤マクロファージの誘導を惹起し,腫瘍内マクロファージの表現型の変化も誘導した.本稿においては,我々が見出したHIF-PH阻害薬による腫瘍増殖抑制作用とそのメカニズムについて概説する.また,マクロファージに対するがん治療薬の研究,開発動向も紹介したい.(著者抄録)

  • HIF-PH阻害薬をフカボリする～何がわかって何がわかっていないのか?～　HIF-PH阻害薬と悪性腫瘍 Domestic conference

    松永 慎司

    日本透析医学会雑誌  2024.05  (一社)日本透析医学会

  • 【医学教育分野別評価における薬理学の役割】薬理学授業における水平・垂直的理解の工夫と試み　階層別学習目標の設定とClinicalKey Student Japan(CKSJ)の活用 Domestic conference

    冨田 修平, 松永 慎司, 山口 雄大

    日本薬理学雑誌  2023.11  (公社)日本薬理学会

    　More details

    2023年2月1日現在,日本医学教育評価機構は,70医学部における医学教育プログラムを評価し国際基準に適合していると認定している.また医学教育の質保証を改良しさらに発展させるために,この認証評価を継続的に受審することが求められる.多くの医学部が1巡目の受審を完了したが,アウトカム基盤型教育に基づく統合カリキュラムへの改変については共通して残された課題の一つである.大阪公立大学では,アウトカム基盤型教育の根幹であるコンピテンシーの達成度を適切に評価するためのマイルストーンの策定を含め,教育プログラムの見直しを進めている.また,設定される卒業時のアウトカムに向かった統合型教育の推進とアクティブラーニングの実践を推進するプログラムへの改定を継続的に進めている.本稿では,大阪公立大学が推進するアウトカム基盤型教育システムに基づき,薬理学教育における水平垂直統合的理解のための工夫と試みについて現状について紹介する.(著者抄録)

  • The effect of PHD inhibitor on tumor microenvironment and tumor immune response Domestic conference

    Shinji Matsunaga, Shuhei Tomita

    The 96th Annual Meeting of the Japanese Pharmacological Society  2022.12  Japanese Pharmacological Society

    　More details

    Presentation type：Symposium, workshop panel (public)  

    Venue：Yokohama  

  • 腫瘍血管形成から見た腫瘍組織微小環境 Domestic conference

    松永 慎司, 冨田 修平

    血管  2022.09  日本心脈管作動物質学会

    　More details

    腫瘍組織は血管形成が未熟な状態であり、低酸素、低栄養状態になっている。生体の低酸素応答を担う低酸素誘導因子はプロリン水酸化酵素(PHD)により酸素依存性の調節を受ける。創傷治癒と血管との関係、血管と腫瘍微小環境との関係、腫瘍微小環境と低酸素との関係、腫瘍組織環境と腫瘍血管正常化および腫瘍免疫との関係について概説した。

  • 【腎性貧血:HIF-PH阻害薬への期待と課題】HIF-PH阻害薬使用時の注意点　悪性腫瘍 Domestic conference

    松永 慎司, 冨田 修平

    腎と透析  2022.08  (株)東京医学社

  • 【低酸素応答シグナルを治療標的とする-PHD阻害薬の治療応用-】PHD阻害薬によるがん微小環境と腫瘍免疫への影響 Domestic conference

    松永 慎司, 冨田 修平

    日本薬理学雑誌  2020.01  (公社)日本薬理学会

▼display all

Industrial Property Rights

  • 腫瘍関連マクロファージ賦活化剤

    冨田　修平、松永　慎司

    　More details

    property_type：Patent 

    Application no：特願2019-143014 

  • 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物

    冨田　修平、松永　慎司

    　More details

    property_type：Patent 

    Application no：2016-171299 

    Announcement no：特開2018-35112 

    Publication no：特開2018-35112 

Grant-in-Aid for Scientific Research

  • 腫瘍組織内自然免疫細胞を利用した治療抵抗性腫瘍に対する治療戦略の開発

    Grant-in-Aid for Scientific Research(C)  2025

  • 腫瘍組織内自然免疫細胞を利用した治療抵抗性腫瘍に対する治療戦略の開発

    Grant-in-Aid for Scientific Research(C)  2024

  • 腫瘍組織内自然免疫細胞を利用した治療抵抗性腫瘍に対する治療戦略の開発

    Grant-in-Aid for Scientific Research(C)  2023

  • 腫瘍微小環境改善薬による抗腫瘍免疫応答制御機構の解明

    Grant-in-Aid for Scientific Research(C)  2020.04

  • 抗癌剤増感作用をもたらす腫瘍内血管再構築機構の解明

    Grant-in-Aid for Young Scientists(B)  2017.04

Outline of education staff

  • 薬理学

Charge of on-campus class subject

  • 人体を考える

    2024   Weekly class   Graduate school

  • 医学研究基本演習

    2024     Graduate school

  • 生体と薬物

    2024     Undergraduate

  • 医学研究基本演習

    2023     Graduate school

  • 生体と薬物

    2023     Undergraduate

  • 医学研究推進コース3

    2023     Undergraduate

  • 生体と薬物

    2022     Undergraduate

  • 医学研究基本演習

    2022     Graduate school

  • 修業実習

    2022     Undergraduate

  • 医学研究基本演習

    2021     Graduate school

  • 生体と薬物

    2021     Undergraduate

  • 薬理学実習（生体と薬物）

    2021   Practical Training   Undergraduate

  • 修業実習

    2021     Undergraduate

  • 薬理学実習

    2020     Undergraduate

  • 修業実習

    2020     Undergraduate

  • 看護科薬理学

    2020     Undergraduate

  • 医学研究基本演習

    2020     Graduate school

  • 薬理学実習

    2019     Undergraduate

  • 看護科薬理学

    2019     Undergraduate

  • 医学研究基本演習

    2019     Graduate school

  • 修業実習

    2019     Undergraduate

  • 薬理学実習

    2018     Undergraduate

  • 医学研究基本演習

    2018     Graduate school

  • 看護科薬理学

    2018     Undergraduate

  • 修業実習

    2017     Undergraduate

  • 薬理学実習

    2017     Undergraduate

  • 看護科薬理学

    2017     Undergraduate

  • 医学研究基本演習

    2017     Graduate school

  • 薬理学実習

    2016     Undergraduate

▼display all

Number of instructed thesis, researches

  • 2020

    [Number of instructed the Master's Program] (previous term)：1  [Number of instructed the Master's Program] (letter term)：1

Other

  • Job Career

    2016.07 - 2017.09